INTS

Intensity Therapeutics, Inc. Common stock

INTS, USA

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

https://www.intensitytherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INTS
stock
INTS

All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy Nasdaq

Read more →
INTS
stock
INTS

Aug Chart Watch: Can INTS stock surprise with earnings upside - Options Play & AI Driven Stock Price Forecasts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$2.9167

Analyst Picks

Strong Buy

1

Buy

2

Hold

2

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.23

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-36.98 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.87 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.33

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 2.35% of the total shares of Intensity Therapeutics, Inc. Common stock

1.

Sentinus, LLC

(0.4236%)

since

2025/06/30

2.

Brown Advisory Holdings Inc

(0.2764%)

since

2025/06/30

3.

Mesirow Fin Investmt Mgmt Intl Equity

(0.2338%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.1547%)

since

2025/06/30

5.

Sigma Planning Corp

(0.147%)

since

2025/06/30

6.

Warberg Asset Management LLC

(0.1454%)

since

2025/06/30

7.

Jane Street Group LLC

(0.0954%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.0918%)

since

2025/07/31

9.

Vanguard Group Inc

(0.0862%)

since

2025/06/30

10.

Blair William & Co

(0.0803%)

since

2025/06/30

11.

One Charles Private Wealth Services, LLC

(0.0676%)

since

2025/06/30

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0593%)

since

2025/07/31

13.

HRT FINANCIAL LLC

(0.0529%)

since

2025/06/30

14.

XTX Topco Ltd

(0.0522%)

since

2025/06/30

15.

QTR Family Wealth, LLC

(0.037%)

since

2025/06/30

16.

Stonebridge Financial Group, LLC

(0.0351%)

since

2025/06/30

17.

EWA, LLC

(0.0341%)

since

2025/06/30

18.

BOOTHBAY FUND MANAGEMENT, LLC

(0.0319%)

since

2025/06/30

19.

State Street Corp

(0.0308%)

since

2025/06/30

20.

Northern Trust Corp

(0.0298%)

since

2025/06/30

21.

Virtu Financial LLC

(0.0291%)

since

2025/06/30

22.

Tower Research Capital LLC

(0.0287%)

since

2025/06/30

23.

Fidelity Series Total Market Index

(0.0227%)

since

2025/07/31

24.

Fidelity Total Market Index

(0.02%)

since

2025/07/31

25.

NT Ext Equity Mkt Idx Fd - L

(0.0166%)

since

2025/06/30

26.

Northern Trust Extended Eq Market Idx

(0.0166%)

since

2025/06/30

27.

Fidelity Nasdaq Composite Index

(0.0147%)

since

2025/07/31

28.

NT Ext Equity Mkt Idx Fd - NL

(0.0127%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0098%)

since

2025/06/30

30.

Spartan Total Market Index Pool G

(0.0055%)

since

2025/07/31

31.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0047%)

since

2025/06/30

32.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0017%)

since

2024/12/31

33.

Northern Trust Wilshire 5000

(0.0005%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.06

Latest Release

Date

2025-09-30

EPS Actual

-0.06

EPS Estimate

-0.06

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.